Protagenic Therapeutics, Inc.
PTIX
$3.44
-$0.08-2.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.32% | -142.46% | 60.11% | 6.83% | -2.87% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -52.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 43.03% | -34.11% | 17.06% | 32.28% | -75.92% |
| Change in Net Operating Assets | -77.82% | 189.64% | 211.82% | -57.47% | 38.22% |
| Cash from Operations | -30.28% | -341.46% | 88.03% | 6.47% | -44.98% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | 33.01% | -49.29% |
| Cash from Investing | -- | -- | -100.00% | 33.01% | -47.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.60% | 405.39% | 612.36% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -93.60% | 405.39% | 612.36% | -- | -- |
| Foreign Exchange rate Adjustments | -100.00% | 500.00% | -150.00% | 0.00% | -77.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -223.36% | 496.57% | 41.38% | 120.35% | -140.20% |